BLOG

Whole Health Series:
Guide for Fertility & Preservation

Maimah Karmo shares her story of fertility and hope after cancer.

Whole Health Series:
Navigating the Stages of Healing in Survivorship

Survivorship isn’t the end of the story—it’s the beginning of a new one.

HEALing Through Advocacy and Allyship

By: Maimah Karmo One of my favorite poets, Rumi said, “The Universe is not outside of you. Look inside yourself; everything that you want, you already are.” I take this […]

Tigerlily Foundation Releases a Powerful New Policy Brief Revealing Egregious Disparities in Screening and Diagnosis for Triple Negative Breast Cancer (TNBC)

November 3, 2021 – A newly released policy brief from the Tigerlily Foundation reveals egregious disparities in screening and diagnosis for Triple Negative Breast Cancer (TNBC) – the most aggressive form of breast cancer that disproportionately affects minority communities and is diagnosed more frequently in younger women and women of color – and offers urgently needed policy solutions to address them.

Study Sponsor: Seagen

This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan. It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab deruxtecan.

Study Sponsor: Sanofi

This study looks at how safe and effective the study drug, atezolizumab, is when given with paclitaxel. To do this, they are comparing the treatment regimen with and without the study medication.

Study Sponsor: Genentech/Hoffmann-La Roche

This study looks at how safe and effective the study drug, atezolizumab, is when given with paclitaxel. To do this, they are comparing the treatment regimen with and without the study medication.

Study Sponsor: Bristol-Myers Squibb

This study is evaluating the efficacy and safety of nivolumab compared to placebo when given with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early-stage breast cancer.